Thomas Pulliam

Thomas Pulliam

Auto-generated profile, based on publicly available information

Thomas Pulliam

Department of Dermatology, University of Washington, Seattle, Washington

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 June 2021 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
EZEdward Zhao
Edward Zhao
MSMatthew R. Stone
Matthew R. Stone
XRXing Ren
Xing Ren
JGJamie Guenthoer
Jamie Guenthoer
KSKimberly S. Smythe
Kimberly S. Smythe
RGRaphael Gottardo
Raphael Gottardo

30 April 2018 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
ACAric Colunga
Aric Colunga
TPThomas Pulliam
Thomas Pulliam
PNPeter P. Nghiem
Peter P. Nghiem
Merkel cell carcinoma (MCC) is a rare (∼2,000 U.S. cases/year) but aggressive neuroendocrine tumor of the skin. For advanced MCC, cytotoxic chemotherapy only infrequently (1 year), suggesting a great need for improved therapeutic options. In 2008, the Merkel cell polyomavirus (MCPyV) was discovered and is clonally integrated in approximately 80% of MCC tumors. The remaining 20% of MCC tumors have large numbers of UV-associated mutations. Importantly, both the UV-induced neoantigens in virus-negative tumors and the MCPyV T antigen oncogenes that are required for virus-positive tumor growth are immunogenic. Indeed, antigen-specific T cells detected in patients are frequently dysfunctional/“exhausted,” and the inhibitory ligand, PD-L1, is often present in MCC tumors. These findings led to recent clinical trials involving PD-1 pathway blockade in advanced MCC. The combined data from these trials involving three PD-1 pathway blocking agents—avelumab, pembrolizumab, and nivolumab—indicated a high frequency of durable responses in treated patients. Of note, prior treatment with chemotherapy was associated with decreased response rates to PD-1 checkpoint blockade. Over the past year, these striking data led to major changes in advanced MCC therapy, including the first-ever FDA drug approval for this disease. Despite these successes, approximately 50% of patients with MCC do not persistently benefit from PD-1 pathway blockade, underscoring the need for novel strategies to broaden antitumor immune responses in these patients. Here, we highlight recent progress in MCC including the underlying mechanisms of immune evasion and emerging approaches to augment the efficacy of PD-1 pathway blockade. Clin Cancer Res; 24(9); 2035–43. ©2017 AACR.

22 July 2020 in Journal of the American Academy of Dermatology
Verified
Journal Article
Closed access
ETErica S. Tarabadkar
Erica S. Tarabadkar
TFTeresa Fu
Teresa Fu
KLKristina Lachance
Kristina Lachance
DHDaniel S. Hippe
Daniel S. Hippe
TPThomas Pulliam
Thomas Pulliam
PNPeter P. Nghiem
Peter P. Nghiem

27 March 2020 in Molecular Carcinogenesis
Verified
Journal Article
Closed access
PDF file
STShira Tabachnick‐Cherny
Shira Tabachnick‐Cherny
TPThomas Pulliam
Thomas Pulliam
CCCandice Church
Candice Church
DKDavid M Koelle
David M Koelle
PNPeter P. Nghiem
Peter P. Nghiem

11 July 2016 in Journal of Natural Products
Verified
Journal Article
Closed access
HLHongbing Liu
Hongbing Liu
KLKatheryn Lohith
Katheryn Lohith
MRMargaret Rosario
Margaret Rosario
TPThomas H. Pulliam
Thomas H. Pulliam
RORobert D. O’connor
Robert D. O’connor
CBCarole Bewley
Carole Bewley

10 January 1994
Verified
Conference Paper
Closed access
SRStuart Rogers
Stuart Rogers
TPThomas Pulliam
Thomas Pulliam